🚨 Sudeep Pharma: From Specialty Ingredients to LFP Battery Materials

Sudeep Pharma Limited is building an interesting dual-engine growth story — combining its established specialty nutrition/pharma ingredients business with a new opportunity in the fast-growing LFP battery materials ecosystem. 📊 FY26 HIGHLIGHTS

• Revenue: ₹642.3 Cr | +28% YoY • Specialty segment contribution: 34% → 44% • Net Debt: only ₹33.6 Cr • ROCE: 22.5% • ROE: 19.4% • Working Capital Cycle: 213 days 🔥 WHAT COULD DRIVE THE NEXT PHASE? 🌍 Direct-to-Customer Model SPL is expanding direct sales in the US and Europe, potentially improving margins while strengthening customer relationships. 🏭 Capacity Expansion The Nandesari Unit IV adds around 51,200 MT capacity for higher-value molecules including gluconates, glycinates and phosphates. ⚡ LFP Battery Opportunity Through Sudeep Advanced Materials, the company is entering battery-grade iron phosphate. The Dahej Phase-I 3.6 Cr, SPL has considerable financial flexibility to fund growth without excessive leverage. ⚠️ KEY RISKS TO WATCH • Working capital cycle at 213 days • Volatility in phosphoric & sulphuric acid prices • Energy and logistics disruptions • Execution risk on new capacity • LFP business still needs to demonstrate meaningful commercial scale 🎯 ANALYST VIEW Sudeep Pharma is gradually moving beyond its traditional specialty-ingredient niche toward a broader specialty materials platform. The combination of specialty ingredients + international expansion + capacity additions + LFP battery optionality creates an interesting long-term growth framework. The balance sheet provides comfort, but the next big test is execution — particularly whether new capacities can ramp up efficiently and generate attractive returns. Neha Gupta SEBI Registered Research Analyst For educational purposes only. Not investment advice. Investors should conduct their own research. #SudeepPharma #LFP #BatteryMaterials #SpecialtyChemicals #Pharma #IndianStocks #Investing